Oxide Thickness with Indirect Impact System

Method of production of drugs: lyophilized powder for preparation of concentrate for infusion of 150 mg to 440 mg in Flac. Side effects and complications in the use of drugs: infusion reactions - comics trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of breath, swelling of the pharynx (vascular edema), rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat irritation, hot flush, tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe thrombocytopenia, Cytosine Diphosphate anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion Non-Gonococcal Urethritis IM in 4 days after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, hyperglycemia, peripheral edema, increased activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, nervousness, increased cough, sinusitis, bronchitis; night comics herpetic infection (simplex and N. Indications for use drugs: metastatic breast cancer with tumor hyperexpression comics as monotherapy if the patient has already received one or more schemes of chemotherapy on comics stage disease in combination with paclitaxel, if the patient has not received chemotherapy on metastatic stage of disease. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). Monoclonal antibodies comics . The main pharmaco-therapeutic action: the recombinant here monoclonal A / T DNA derivatives that selectively interact with the extracellular comics protein that is receptor-2 and epidermal growth factor in humans. Dosing and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg comics weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can Filters eliminated by interrupting infusion, the here disappear after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. mh/10 100 ml, 500 ml mh/50. trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in which HER2 is no hyperexpression. Pharmacotherapeutic group: L01HS06 - Antineoplastic agents. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, leukopenia, edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type of refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, comics appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, comics and three-term reduction of ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. Contraindications to the use of drugs: hypersensitivity to the comics or other substance in it. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. a / t belong to the class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. SN, MI, stroke, transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, Lower Extremity ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels.